SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind has announced the publication of a patent application in Mexico for the innovative combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines. The patent refers to SciSparc’s innovative combination therapy of N-Acylethanolamines and Clearmind’s MEAI, addressing binge behaviour, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRC:
- Clearmind announces publication of patent for binge behavior treatment
- SciSparc Granted Nasdaq Compliance Extension
- SciSparc granted 180-day extension to regain Nasdaq compliance
- SciSparc: AutoMax enters direct import market with $13M first shipment of JAC EV
- SciSparc says MitoCareX expands research to pancreatic cancer